NOTE: Information in this document marked with an "[*]" has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
March 7, 2002
TABLE OF CONTENTS
PAGE
----
1. Purchase and Sale of Stock...................................................................................1
1.1 Sale and Issuance of Series A Preferred Stock.......................................................1
1.2 Closings............................................................................................2
1.3 Use of Proceeds.....................................................................................3
1.4 Sales of Investor Common Stock......................................................................3
2. Representations and Warranties of the Company Applicable to each Closing.....................................3
2.1 Organization; Good Standing; Qualification..........................................................3
2.2 Corporate Power.....................................................................................3
2.3 Authorization.......................................................................................4
2.4 Valid Issuance of Series A Preferred Stock..........................................................4
2.5 Capitalization and Voting Rights....................................................................4
2.6 Subsidiaries........................................................................................5
2.7 Compliance with Other Instruments...................................................................5
2.8 Governmental Consent, etc...........................................................................5
2.9 Offering............................................................................................6
2.10 Agreements; Action..................................................................................6
2.11 Obligations to Related Parties......................................................................6
2.12 Title to Properties and Assets......................................................................7
2.13 Intellectual Property...............................................................................7
2.14 Employees; Employee Benefit Plans...................................................................7
2.15 Proprietary Information and Inventions Assignment Agreement.........................................8
2.16 Litigation..........................................................................................8
2.17 Insurance...........................................................................................8
2.18 Registration Rights.................................................................................8
2.19 Brokers or Finders; Other Offers....................................................................8
2.20 Permits.............................................................................................9
2.21 Financial Statements................................................................................9
2.22 Tax Returns, Payments and Elections.................................................................9
2.23 Corporate Documents.................................................................................9
2.24 Minute Books.......................................................................................10
2.25 Section 83(b) Elections............................................................................10
2.26 Qualified Small Business Stock.....................................................................10
2.27 Environmental and Safety Laws......................................................................10
2.28 Disclosure.........................................................................................10
3. Representations and Warranties of the Company Applicable to Milestone Investment Closings...................10
3.1 Purchase Entirely for Own Account..................................................................10
3.2 Reliance upon Company's Representations............................................................11
3.3 Disclosure of Information..........................................................................11
-i-
TABLE OF CONTENTS
(CONTINUED)
PAGE
3.4 Investment Experience; Economic Risk...............................................................11
3.5 Residency..........................................................................................11
3.6 Restricted Securities..............................................................................11
3.7 Brokers or Finders.................................................................................12
3.8 Further Limitations on Disposition.................................................................12
3.9 Legends............................................................................................12
4. Representations, Warranties and Covenants of the Investor...................................................12
4.1 Power; Authorization...............................................................................12
4.2 Purchase Entirely for Own Account..................................................................13
4.3 Reliance upon Investor's Representations...........................................................13
4.4 Disclosure of Information..........................................................................13
4.5 Investment Experience; Economic Risk...............................................................13
4.6 Accredited Investor Status.........................................................................13
4.7 Residency..........................................................................................14
4.8 Restricted Securities..............................................................................14
4.9 Brokers or Finders.................................................................................14
4.10 Further Limitations on Disposition.................................................................14
4.11 Legends............................................................................................14
5. Conditions to Closing of the Investor.......................................................................15
5.1 Conditions Applicable to All Closings..............................................................15
5.2 Conditions Applicable to the Closing of the Initial Investment.....................................16
5.3 Conditions Applicable to the Closing of each Quarterly Investment..................................17
5.4 Conditions Applicable to the Closing of the First Milestone Investment.............................17
5.5 Conditions Applicable to the Closing of each Second Milestone Investment...........................17
5.6 Conditions Applicable to the Closing of each Third Milestone Investment............................18
6. Conditions to Closing of Company............................................................................18
6.1 Conditions Applicable to All Closings..............................................................18
6.2 Conditions Applicable to the Closing of the Initial Investment.....................................18
7. Investor's Purchase Right...................................................................................19
7.1 Purchase Option....................................................................................19
7.2 Acquisition Agreement..............................................................................20
7.3 Assignment of Option...............................................................................21
7.4 Further Agreements.................................................................................21
7.5 Stockholder Execution of this Agreement............................................................21
8. Miscellaneous...............................................................................................21
8.1 Governing Law......................................................................................21
8.2 Survival of Warranties.............................................................................21
-ii-
TABLE OF CONTENTS
(CONTINUED)
PAGE
8.3 Successors and Assigns.............................................................................21
8.4 Entire Agreement...................................................................................22
8.5 Amendment..........................................................................................22
8.6 Notices............................................................................................22
8.7 Delays or Omissions................................................................................22
8.8 Finder's Fees......................................................................................22
8.9 Expenses...........................................................................................23
8.10 Attorney's Fees....................................................................................23
8.11 Severability.......................................................................................23
8.12 Interpretation.....................................................................................23
8.13 Counterparts.......................................................................................23
8.14 Telecopy Execution and Delivery....................................................................23
8.15 Adjustments........................................................................................23
Schedules:
A - Schedule of Stockholders
Exhibits:
A - Amended and Restated Certificate of Incorporation
B - Schedule of Exceptions
C - Investors' Rights Agreement
D - Right of First Refusal and Co-Sale Agreement
E - Form of Proprietary Information and Inventions Assignment
Agreement
F - Opinion of Company Counsel
G - Repurchase Option Agreement
-iii-
NOTE: Information in this document marked with an "[*]" has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
This
Series A Preferred Stock Purchase Agreement (this "Agreement") is
made as of March 7, 2002 (the "Effective Date") by and among VirRx, Inc., a
Delaware corporation (the "Company"), Introgen Therapeutics, Inc., a
Delaware
corporation (the "Investor"), and the individuals and entities listed on
Schedule A hereto (each a "Stockholder" and, collectively, the "Stockholders").
1. Purchase and Sale of Stock.
1.1 Sale and Issuance of Series A Preferred Stock.
(a) The Company shall adopt and file with the
Delaware Secretary of State on or before the Closing (as defined in Section
1.2(f)) of the Initial Investment (as defined in Section 1.2(a)) the Amended and
Restated Certificate of Incorporation in the form attached to this Agreement as
Exhibit A (the "Restated Certificate").
(b) The Company has authorized the sale and issuance
of up to [*] shares (the "Series A Shares") of its Series A Preferred Stock, par
value $0.01 per share (the "Series A Preferred Stock"), pursuant to this
Agreement.
(c) Subject to the terms and conditions of this
Agreement, the Investor agrees to purchase at each Closing (as defined in
Section 1.2(f)) and the Company agrees to sell and issue to the Investor at each
Closing that number of shares of the Company's Series A Preferred Stock to be
sold in the applicable Closing at a purchase price of [*] per share of Series A
Preferred Stock. The purchase price per share of Series A Preferred Stock shall
be paid by the Investor in cash at each Closing other than the Closings of the
Milestone Investments (as defined in Section 1.2(e)). The purchase price per
share of Series A Preferred Stock at each Closing of a Milestone Investment
shall be paid by, and at the sole discretion of, the Investor in either cash or
by issuing shares of the Investor's Common Stock, par value $0.001 per share
("Investor Common Stock"), valued at the Fair Market Value (as defined below)
thereof. The shares of Series A Preferred Stock to be sold to the Investor
hereunder are hereinafter referred to as the "Shares".
(d) The "Fair Market Value" of Investor Common Stock
means, with respect to the date of any Closing:
(i) if the Investor Common Stock is then
traded on a national securities exchange or the Nasdaq Stock Market (or a
similar national quotation system), then the Fair Market Value of the Investor
Common Stock shall be deemed to be the average of the closing prices of the
Investor Common Stock on such exchange or system over the thirty (30) day
trading period ending three (3) trading days prior to the date of the applicable
Closing;
(ii) if the Investor Common Stock is then
actively traded over-the-counter, then the Fair Market Value of the Investor
Common Stock shall be deemed to be the average of the closing bid prices of the
Investor Common Stock over the thirty (30) day trading period ending three (3)
trading days prior to the date of the applicable Closing; and
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
(iii) otherwise, the Fair Market Value of
the Investor Common Stock shall be the fair market value of the Investor Common
Stock as of the date of the applicable Closing, as determined in good faith by
the Investor's Board of Directors.
1.2 Closings.
(a) The initial purchase and sale of the Shares shall
take place on the date of this Agreement, at which time the Investor shall
purchase [*] Shares (the "Initial Investment").
(b) Beginning on April 1, 2002, and upon each July 1,
October 1, January 1 and April 1 thereafter through January 1, 2006, the
Investor will purchase, and the Company will sell to the Investor, [*] Shares
(the "Quarterly Investments").
(c) Upon a date mutually agreed to by the Company and
the Investor, but in any event no later than [*] after [*] first completion of a
Phase I clinical study of the first Licensed Product (as defined in the
Collaboration and License Agreement) by the Company, the Investor will purchase,
and the Company will sell to the Investor, [*] Shares (the "First Milestone
Investment"). It is understood that the First Milestone Investment shall be made
[*], and that the total investment under this Section 1.2(c) shall not exceed
[*] Shares.
(d) Upon a date mutually agreed to by the Company and
the Investor, but in any event no later than [*] after [*] first completion
of a Phase II clinical study of the first Licensed Product (as defined in the
Collaboration and License Agreement) for each of the [*] defined in the
Collaboration and License Agreement) by the Company, the Investor will purchase,
and the Company will sell to the Investor, [*] Shares (the "Second Milestone
Investments"), subject to the limitations of the Collaboration and License
Agreement. It is understood that a Second Milestone Investment shall be made
only [*] and that the total investment under this Section 1.2(d) shall not
exceed [*] Shares.
(e) Upon a date mutually agreed to by the Company and
the Investor, but in any event no later than [*] after [*] first completion of a
Phase III clinical study of the first Licensed Product (as defined in the
Collaboration and License Agreement) for each of the [*] (as defined in the
Collaboration and License Agreement) by the Company, the Investor will purchase,
and the Company will sell to the Investor, [*] Shares (the "Third Milestone
Investments"), subject to the limitations of the Collaboration and License
Agreement. It is understood that a Third Milestone Investment shall be made only
[*], and that the total investment under this Section 1.2(e) shall not exceed
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-2-
[*] shares. (Collectively, the First Milestone Investment, Second Milestone
Investments and Third Milestone Investments are referred to in this Agreement as
the "Milestone Investments.")
(f) The closing of the Initial Investment, each
Quarterly Investment and each Milestone Investment (each a "Closing," and,
collectively, the "Closings") shall take place at the offices of ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, Professional Corporation, located at 8911 Capital of Texas
Highway N., Westech 360, Suite 3350, Austin, Texas 78759-7247, at 4:00 PM local
time, on the date of the applicable Closing.
(g) At each Closing, the Company shall deliver to the
Investor a certificate representing the Shares that the Investor is purchasing
against payment of the purchase price therefor by check, wire transfer, shares
of Investor Common Stock (if the Closing is of a Milestone Investment), or any
combination thereof.
1.3 Use of Proceeds. The Company agrees that it shall use the
proceeds it receives from the sale of the Shares at each Closing, or from the
sale of any Investor Common Stock received pursuant to this Agreement, solely
for the purpose of conducting (a) the Research Program (as defined in the
Collaboration and License Agreement (as defined in Section 5.2(g) below)) to be
conducted pursuant to the Collaboration and License Agreement or (b) Other
Funded Research (as defined in, and only to the extent permitted under, the
Collaboration and License Agreement).
1.4 Sales of Investor Common Stock. If the Company proposes to
sell any Investor Common Stock received by the Company at a Milestone Closing,
then, at least 10 calendar days prior to the date of such proposed sale, the
Company shall notify the Investor of such proposed sale. The Company agrees to
consult with the Investor regarding the terms, conditions and timing of any such
proposed sale in order to facilitate the orderly sale of the Investor Common
Stock proposed to be sold. The Investor agrees to use its commercially
reasonable efforts to facilitate the proposed sale, including providing access
to (a) the Investor's investment bankers and (b) institutional investors whom
the Investor knows desire to purchase Investor Common Stock in a block
transaction.
2. Representations and Warranties of the Company Applicable to each
Closing.
Except as set forth on the Schedule of Exceptions attached to this
Agreement as Exhibit B (the "Schedule of Exceptions"), the Company represents
and warrants to the Investor as of the date of each Closing, as follows:
2.1 Organization; Good Standing; Qualification. The Company is
a corporation duly organized and validly existing and in good standing under the
laws of the State of
Delaware. The Company is duly qualified and is authorized
to transact business and is in good standing as a foreign corporation in the
State of Missouri and in each jurisdiction in which the failure to so qualify
would have a material adverse effect on the Company's business, properties or
financial condition.
2.2 Corporate Power. The Company has all requisite legal and
corporate power and authority (i) to own and operate its properties and assets
and to carry on its business as presently
----------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-3-
conducted, (ii) to execute and deliver this Agreement, the Investors' Rights
Agreement in the form attached hereto as Exhibit C (the "Investors' Rights
Agreement") and the Right of First Refusal and Co-Sale Agreement in the form
attached hereto as Exhibit D (the "Co-Sale Agreement") (collectively, other than
this Agreement, the "Ancillary Agreements"), (iii) to sell and issue the Shares
and the Common Stock issuable upon conversion thereof and (iv) to carry out and
perform the provisions of this Agreement and the Ancillary Agreements.
2.3 Authorization. All corporate action on the part of the
Company, its officers, directors and stockholders necessary for the
authorization, execution, delivery of this Agreement and the Ancillary
Agreements, the performance of all obligations of the Company hereunder and
thereunder, and the authorization, issuance (or reservation for issuance), sale
and delivery of the Shares and the Common Stock issuable upon conversion thereof
has been taken or will be taken prior to the Closing of the Initial Investment.
This Agreement and the Ancillary Agreements, when executed and delivered by the
Company, will constitute valid and binding obligations of the Company,
enforceable in accordance with their respective terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of
general application affecting enforcement of creditors' rights generally, (ii)
as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) to the extent the
indemnification provisions contained in the Investors' Rights Agreement may be
limited by applicable laws and principles of public policy.
2.4 Valid Issuance of Series A Preferred Stock. The Shares,
when issued, sold and delivered in accordance with the terms of this Agreement
for the consideration expressed herein, will be duly authorized, validly issued,
fully paid and nonassessable, and will be free of restrictions on transfer other
than restrictions on transfer under this Agreement and the Ancillary Agreements
and under applicable state and federal securities laws. The Common Stock
issuable upon conversion of the Shares has been duly authorized, validly
reserved for issuance and, upon issuance in accordance with the terms of the
Restated Certificate, will be validly issued, fully paid and nonassessable, and
will be free of restrictions on transfer other than restrictions on transfer
under this Agreement and the Ancillary Agreements and under applicable state and
federal securities laws.
2.5 Capitalization and Voting Rights. The authorized capital
of the Company consists, or will consist immediately prior to the Closing of the
Initial Investment, of:
(a) Preferred Stock. [*] shares of Preferred Stock,
par value $0.01, of which [*] shares have been designated Series A Preferred
Stock, none of which are issued and outstanding. The relative rights, privileges
and preferences of each authorized series of Preferred Stock will be as stated
in the Restated Certificate.
(b) Common Stock. [*] shares of Common Stock, par
value $0.01 ("Common Stock"), [*] of which shares are issued and outstanding.
(c) The outstanding shares of Common Stock have been
duly authorized and validly issued, are fully paid and nonassessable, and were
issued in accordance with the
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-4-
registration or qualification provisions of the Securities Act of 1933, as
amended (the "Securities Act"), and any applicable state securities laws or
pursuant to valid exemptions therefrom.
(d) Except for (i) the conversion privileges of the
Series A Preferred Stock, (ii) the rights provided in the Investors' Rights
Agreement and (iii) outstanding options to purchase up to [*] shares of Common
Stock under the VirRx Incentive Stock Plan (the "Stock Plan"), there are no
outstanding options, warrants, rights (including conversion or preemptive
rights) or agreements for the purchase or acquisition from the Company of any of
its securities. The Company has reserved a total of [*] shares of its Common
Stock for options and stock purchase rights granted under the Stock Plan. No
stock plan, stock purchase, stock option or other agreement or understanding
between the Company and any holder of any of the Company's equity securities or
rights to purchase the Company's equity securities provides for acceleration or
other changes in the vesting provisions or other terms of such securities, as
the result of any merger, sale of stock or assets, change in control or other
similar transaction by the Company. The Company is not a party or subject to any
agreement or understanding, and, to the Company's knowledge, there is no
agreement or understanding between any persons that affects or relates to the
voting or giving of written consents with respect to any security or the voting
by a director of the Company.
2.6 Subsidiaries. The Company does not own or control,
directly or indirectly, any interest in any corporation, partnership, limited
liability company, association or other business entity. The Company is not a
participant in any joint venture, partnership or similar arrangement, other than
with the Investor.
2.7 Compliance with Other Instruments. The Company is not in
violation or default of any provision of its charter or bylaws (both as amended
to date) or of any provision of any mortgage, indenture, agreement, instrument
or contract to which it is a party or by which it is bound or, to the best of
its knowledge, of any federal or state judgment, order, writ, decree, statute,
rule or regulation applicable to the Company. The execution, delivery and
performance by the Company of this Agreement and the Ancillary Agreements, and
the consummation of the transactions contemplated hereby and thereby, will not
result in any such violation or be in conflict with or constitute, with or
without the passage of time or giving of notice, either a default under any such
provision or an event that results in the creation of any lien, charge or
encumbrance upon any assets of the Company or the suspension, revocation,
impairment, forfeiture or nonrenewal of any material permit, license,
authorization or approval applicable to the Company, its business or operations
or any of its assets or properties.
2.8 Governmental Consent, etc. No consent, approval,
qualification, order or authorization of, or filing with, any federal, state or
local governmental authority on the part of the Company is required in
connection with the Company's execution, delivery or performance of this
Agreement, the offer, sale or issuance of the Shares or the issuance of the
Common Stock issuable upon conversion of the Shares, except (i) filing of the
Restated Certificate with the
Delaware Secretary of State and (ii) such filings
as have been made prior to the Closing, except any notices of sale required to
be filed with the Securities and Exchange Commission under Regulation D of the
Securities Act, or such post-Closing filings as may be required under applicable
state securities laws, which will be timely filed with the applicable periods
therefor.
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-5-
2.9 Offering. Subject in part to the truth and accuracy of the
Investor's representations set forth in Section 4 of this Agreement, the offer,
sale and issuance of the Shares as contemplated by this Agreement are exempt
from the registration requirements of Section 5 of the Securities Act, and all
applicable state securities laws, and neither the Company nor any authorized
agent acting on its behalf will take any action hereafter that would cause the
loss of such exemption.
2.10 Agreements; Action.
(a) Except for agreements explicitly contemplated by
this Agreement or the Ancillary Agreements, there are no agreements,
understandings or proposed transactions between the Company and any of its
officers, directors, affiliates, or any affiliate thereof.
(b) There are no contracts, agreements, instruments,
leases, commitments, understandings, proposed transactions, judgments, orders,
writs or decrees to which the Company is a party or by which it is bound that
may involve (i) obligations (contingent or otherwise) of, or payments to the
Company in excess of, $5,000 or (ii) provisions restricting or affecting the
development, manufacture or distribution of the Company's products or services
or (iii) indemnification by the Company with respect to infringements of
proprietary rights.
(c) The Company has not (i) declared or paid any
dividends or authorized or made any distribution upon or with respect to any
class or series of its capital stock, (ii) incurred any indebtedness for money
borrowed or any other liabilities individually in excess of $5,000 or, in the
case of indebtedness and/or liabilities individually less than $5,000, in excess
of $15,000 in the aggregate, (iii) made any loans or advances to any person,
other than ordinary advances for travel expenses, or (iv) sold, exchanged or
otherwise disposed of any of its assets or rights, other than the sale of its
products or services in the ordinary course of business.
(d) For the purposes of subsections (b) and (c)
above, all indebtedness, liabilities, agreements, understandings, instruments,
contracts and proposed transactions involving the same person or entity
(including persons or entities the Company has reason to believe are affiliated
therewith) shall be aggregated for the purpose of meeting the individual minimum
dollar amounts of such subsections.
2.11 Obligations to Related Parties. No employee, officer,
director or stockholder of the Company or member of his or her immediate family
is indebted to the Company, nor is the Company indebted (or committed to make
loans or extend or guarantee credit) to any of them other than (i) for payment
of salary for services rendered, (ii) reimbursement for reasonable expenses
incurred on behalf of the Company and (iii) for other standard employee benefits
made generally available to all employees (including stock option agreements
outstanding under any stock option plan approved by the Company's Board of
Directors and stock purchase agreements approved by the Company's Board of
Directors). None of such persons has any direct or indirect ownership interest
in any firm or corporation with which the Company is affiliated or with which
the Company has a business relationship, or any firm or corporation that
competes with the Company, except that employees, officers, directors or
stockholders of the Company and members of their immediate families may own
stock in publicly traded companies that may compete with the Company. No
-6-
employee, officer, director or stockholder, or any member of their immediate
families, is, directly or indirectly, interested in any material contract with
the Company (other than such contracts as relate to any such person's ownership
of capital stock or other securities of the Company).
2.12 Title to Properties and Assets. The Company owns its
property and assets free and clear of all mortgages, liens, claims, and
encumbrances other than (i) for liens for current taxes not yet delinquent, (ii)
for liens imposed by law and incurred in the ordinary course of business for
obligations not past due to carriers, warehousemen, laborers, materialmen and
the like, (iii) for liens in respect of pledges or deposits under workers'
compensation laws or similar legislation or (iv) for minor defects in title,
none of which, individually or in the aggregate, materially interferes with the
use of such property. With respect to the property and assets it leases, the
Company is in compliance with such leases and, holds a valid leasehold interest
free of any liens, claims, or encumbrances, subject to clauses (i)-(iv) above.
2.13 Intellectual Property. The Company owns or possesses
sufficient legal rights to all patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information, and proprietary rights and
processes (collectively, "Intellectual Property") necessary for its business as
now conducted and as presently proposed to be conducted, and, to the best of its
knowledge, without any conflict with or infringement of the rights of others.
The Schedule of Exceptions contains a complete list of the Company's patents and
pending patent applications. There are no outstanding options, licenses, or
agreements of any kind relating to the Company's Intellectual Property, nor is
the Company bound by or a party to any options, licenses or agreements of any
kind with respect to the Intellectual Property of any other person or entity
with the exception of shrink-wrap, click-wrap or similar widely-available
commercial end-user software licenses. The Company has not received any
communications alleging that the Company has violated or, by conducting its
business as presently proposed, would violate any of the Intellectual Property
of any other person or entity. The Company is not aware that any of its
employees is obligated under any contract (including licenses, covenants or
commitments of any nature) or other agreement, or subject to any judgment,
decree or order of any court or administrative agency, that would interfere with
the use of his or her best efforts to promote the interests of the Company or
that would conflict with the Company's business as presently proposed to be
conducted. Neither the execution nor delivery of this Agreement or the Ancillary
Agreements, nor the carrying on of the Company's business by the employees of
the Company, nor the conduct of the Company's business as presently proposed,
will, to the Company's knowledge, conflict with or result in a breach of the
terms, conditions or provisions of, or constitute a default under, any contract,
covenant or instrument under which any of such employees is now obligated. The
Company does not believe it is or will be necessary to utilize any inventions of
any of its employees (or people it currently intends to hire) made prior to
their employment by the Company.
2.14 Employees; Employee Benefit Plans. To the Company's
knowledge, there is no strike, labor dispute or union organization activities
pending or threatened between it and its employees. None of the Company's
employees belongs to any union or collective bargaining unit. The Company has
complied in all material respects with all applicable state and federal equal
opportunity and other laws related to employment. To the Company's knowledge, no
employee of the Company is or will be in violation of any judgment, decree, or
order, or any term of any
-7-
employment contract, patent disclosure agreement, or other contract or agreement
relating to the relationship of any such employee with the Company, or any other
party because of the nature of the business presently conducted or presently
proposed to be conducted by the Company. The Company does not have any Employee
Benefit Plan as defined in the Employee Retirement Income Security Act of 1974,
as amended. The Company is not aware that any officer or key employee, or that
any group of key employees, intends to terminate their employment with the
Company, nor does the Company have a present intention to terminate the
employment of any of the foregoing. Subject to general principles related to
wrongful termination of employees, the employment of each officer and employee
of the Company is terminable at the will of the Company.
2.15 Proprietary Information and Inventions Assignment
Agreement. Each current or former consultant of the Company that assists or
assisted with the development of the Company's Intellectual Property or has or
had access to the Company's Intellectual Property and each current and former
employee and officer of the Company has executed a proprietary information and
inventions assignment agreement in the form or forms attached hereto as Exhibit
E. The Company, after reasonable investigation, is not aware that any of its
employees, officers or consultants are in violation thereof. No current or
former employee or officer has excluded works or inventions made prior to his or
her employment with the Company from his or her assignment of inventions
pursuant to such employee's proprietary information and inventions assignment
agreement.
2.16 Litigation. There is no action, suit, proceeding or
investigation pending or, to the Company's knowledge, currently threatened
against the Company, nor, to the Company's knowledge is there any reasonable
basis therefor. The foregoing includes, without limitation, any action, suit,
proceeding or investigation pending or, to the Company's knowledge, currently
threatened involving the prior employment of any of the Company's employees,
their use in connection with the Company's business of any information or
techniques allegedly proprietary to any of their former employers or their
obligations under any agreement with their former employers. The Company is not
a party to or, to its knowledge, named in or subject to any order, writ,
injunction, judgment or decree of any court, government agency or
instrumentality. There is no action, suit, proceeding or investigation by the
Company currently pending or that the Company currently intends to initiate.
2.17 Insurance. The Company has in full force and effect fire
and casualty insurance policies, with extended coverage, sufficient in amount
(subject to reasonable deductibles) to allow it to replace any of its properties
that might be damaged or destroyed.
2.18 Registration Rights. Except as set forth in the
Investors' Rights Agreement, the Company is presently not under any obligation
and has not granted any rights to register under the Securities Act any of its
presently outstanding securities or any of its securities that may hereafter be
issued.
2.19 Brokers or Finders; Other Offers. The Company has not
incurred, and will not incur, directly or indirectly, as a result of any action
taken by the Company, any liability for brokerage or finders' fees or agents'
commissions or any similar charges in connection with this Agreement.
-8-
2.20 Permits. The Company has all franchises, permits,
licenses and any similar authority necessary for the conduct of its business as
presently conducted by it, the lack of which could result in a material adverse
effect on the Company's business, properties or financial condition, and the
Company believes it can obtain, without undue burden or expense, any similar
authority for the conduct of its business as presently proposed to be conducted.
The Company is not in default in any material respect under any of such
franchises, permits, licenses or other similar authority.
2.21 Financial Statements. The Company has delivered to the
Investor its unaudited financial statements (balance sheet and profit and loss
statement) as at and for the period from the Company's inception through
December 31, 2001 and as at and for the one-month period ended January 31, 2002
(the "Financial Statements"). The Financial Statements fairly present the
financial condition and operating results of the Company as of the dates, and
for the periods, indicated therein. Except as set forth in the Financial
Statements, the Company has no material liabilities, contingent or otherwise,
other than liabilities incurred in the ordinary course of business subsequent to
January 31, 2002, which individually or in the aggregate are not material to the
financial condition or operating results of the Company. The Company is not a
guarantor or indemnitor of any indebtedness of any other person, firm or
corporation. The Company maintains and will continue to maintain a standard
system of accounting established and administered in accordance with generally
accepted accounting principles.
2.22 Tax Returns, Payments and Elections. The Company has
filed all tax returns and reports as required by law. These returns and reports
are true and correct in all material respects. The Company has paid all taxes
and other assessments due, except those contested by it in good faith that are
listed in the Schedule of Exceptions. The provision for taxes of the Company as
shown in the Financial Statements is adequate for taxes due or accrued as of the
date thereof. The Company has not elected pursuant to the Internal Revenue Code
of 1986, as amended (the "Code"), to be treated as a Subchapter S corporation or
a collapsible corporation pursuant to Section 1362(a) or Section 341(f) of the
Code, nor has it made any other elections pursuant to the Code (other than
elections that relate solely to methods of accounting, depreciation or
amortization) that would have a material effect on the Company's business,
properties or financial condition. The Company has never had any tax deficiency
proposed or assessed against it and has not executed any waiver of any statute
of limitations on the assessment or collection of any tax or governmental
charge. None of the Company's federal income tax returns and none of its state
income or franchise tax or sales or use tax returns has ever been audited by
governmental authorities. Since the date of the Financial Statements, the
Company has made adequate provisions on its books of account for all taxes,
assessments and governmental charges with respect to its business, properties
and operations for such period. The Company has withheld or collected from each
payment made to each of its employees, the amount of all taxes (including, but
not limited to, federal income taxes, Federal Insurance Contribution Act taxes
and Federal Unemployment Tax Act taxes) required to be withheld or collected
therefrom, and has paid the same to the proper tax receiving officers or
authorized depositaries.
2.23 Corporate Documents. Except for amendments necessary to
satisfy representations and warranties or conditions contained herein (the form
of which amendments has
-9-
been approved by the Investor), the Company's charter and bylaws are in the form
previously provided to special counsel for the Investor.
2.24 Minute Books. The copy of the Company's minute books
provided to the Investor's special counsel contains minutes of all meetings of
directors and stockholders and all actions by written consent without a meeting
by the directors and stockholders since the date of incorporation and accurately
reflects all actions by the directors and stockholders with respect to all
transactions referred to in such minutes in all material respects.
2.25 Section 83(b) Elections. To its knowledge, all
individuals who have purchased shares of the Company's Common Stock under
agreements that provide for the vesting of such shares have timely filed
elections under Section 83(b) of the Code and any analogous provisions of
applicable state tax laws.
2.26 Qualified Small Business Stock. As of the date of this
Agreement, the Shares constitute "qualified small business stock" within the
meaning of Section 1202 of the Code. The Company will use its reasonable best
efforts to comply with any applicable filing or reporting requirements of
Section 1202 and any regulations promulgated thereunder.
2.27 Environmental and Safety Laws. To its knowledge, the
Company is not in violation of any applicable statute, law or regulation
relating to the environment or occupational health and safety, and to its
knowledge, no material expenditures are or will be required in order to comply
with any such existing statute, law or regulation.
2.28 Disclosure. The Company has provided the Investor with
all the information reasonably available to it without undue expense that the
Investor has requested for deciding whether to purchase the Shares and all
information that the Company believes is reasonably necessary to enable the
Investor to make such decision. Neither this Agreement, the Ancillary
Agreements, nor any other written statements or certificates made or delivered
in connection herewith, when taken as a whole, contains any untrue statement of
a material fact or omits to state a material fact necessary to make the
statements contained herein or therein not misleading in light of the
circumstances under which they were made.
3. Representations and Warranties of the Company Applicable to
Milestone Investment Closings.
The Company represents and warrants to the Investor as of the date of
the Closing of each Milestone Investment at which the Company receives Investor
Common Stock pursuant to Section 1.1(c), as follows:
3.1 Purchase Entirely for Own Account. The Company hereby
agrees that the Investor Common Stock will be acquired for investment for the
Company's own account, not as a nominee or agent, and not with a view to the
resale or distribution of any part thereof, and the Company further agrees that
it has no present intention of selling, granting any participation in, or
-10-
otherwise distributing the same. By executing this Agreement, the Company
further represents that the Company does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant
participations to the person or to any third person with respect to any of the
Investor Common Stock.
3.2 Reliance upon Company's Representations. The Company
understands that the Investor Common Stock is not registered under the
Securities Act on the ground that the sale provided for in this Agreement and
the issuance of the Investor Common Stock hereunder is exempt from registration
under the Securities Act pursuant to Section 4(2) thereof, and that the
Investor's reliance on such exemption is predicated on the Company's
representations set forth herein.
3.3 Disclosure of Information. The Company believes it has
received all the information the Company considers necessary or appropriate for
deciding whether to purchase the Investor Common Stock. The Company has had an
opportunity to ask questions and receive answers from the Investor regarding the
terms and conditions of the offering of the Investor Common Stock and the
Investor's business, properties, prospects and financial condition and to obtain
additional information (to the extent the Investor possessed such information or
could acquire it without unreasonable effort or expense) necessary to verify the
accuracy of any information furnished to the Company or to which the Company had
access.
3.4 Investment Experience; Economic Risk. The Company
understands that an investment in the Investor involves substantial risks. The
Company is experienced in evaluating and investing in private placement
transactions of securities of companies in a similar stage of development to
that of the Investor and acknowledges that the Company is able to fend for
itself. The Company has such knowledge and experience in financial and business
matters that the Company is capable of evaluating the merits and risks of the
investment in the Investor Common Stock. The Company can bear the economic risk
of the Company's investment and is able, without impairing the Company's
financial condition, to hold the Investor Common Stock for an indefinite period
of time and to suffer a complete loss of the Company's investment.
3.5 Residency. The state of the Company's principal place of
business is Missouri.
3.6 Restricted Securities. The Company understands that the
Investor Common Stock is characterized as "restricted securities" under the
federal securities laws inasmuch as they are being acquired from the Investor in
a transaction not involving a public offering and that under such federal
securities laws and applicable regulations such Investor Common Stock may be
resold without registration under the Securities Act only in certain limited
circumstances. In this connection, the Company represents that it is aware of
the provisions of Rule 144 promulgated under the Securities Act which permit
limited resale of shares purchased in a private placement subject to the
satisfaction of certain conditions, including, among other things, the existence
of a public market for the shares, the availability of certain current public
information about the Investor, the resale occurring not less than one year
after a party has purchased and paid for the security to be sold, the sale being
effected through a "broker's transaction" or in transactions directly with a
"market maker"
-11-
and the number of shares being sold during any three-month period not exceeding
specified limitations.
3.7 Brokers or Finders. The Investor has not, and will not,
incur, directly or indirectly, as a result of any action taken by the Company,
any liability for brokerage or finders' fees or agents' commissions or any
similar charges in connection with this Agreement.
3.8 Further Limitations on Disposition. Without in any way
limiting the representations set forth above, the Company further agrees not to
make any disposition of all or any portion of the Investor Common Stock unless
and until (X) there is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made
in accordance with such registration statement or (Y) the Company shall have
notified the Investor of the proposed disposition and shall have furnished the
Investor with a detailed statement of the circumstances surrounding the proposed
disposition, and if reasonably requested by the Investor, the Company shall have
furnished the Investor with an opinion of counsel, reasonably satisfactory to
the Investor, that such disposition will be exempt from registration under the
Securities Act. Notwithstanding the foregoing, no such registration statement or
opinion of counsel shall be necessary for a transfer by the Investor to any
person that directly, or indirectly through one or more intermediaries, controls
or is controlled by, or is under common control with, the Investor; provided,
however, that, in such case, the transferee agrees in writing to be subject to
the terms of this Agreement to the same extent as if it were the Company
hereunder.
3.9 Legends. The Company understands and agrees that the
certificates evidencing the Investor Common Stock shall bear the following
legend (in addition to any legend required under applicable state securities
laws):
"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY
STATE, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED
UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND/OR APPLICABLE STATE SECURITIES
LAWS, OR UNLESS THE CORPORATION HAS RECEIVED AN OPINION OF COUNSEL OR OTHER
EVIDENCE, REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH
REGISTRATION IS NOT REQUIRED."
4. Representations, Warranties and Covenants of the Investor. The
Investor hereby represents, warrants and covenants to the Company as follows:
4.1 Power; Authorization. The Investor has all requisite power
and authority to execute and deliver this Agreement and the Ancillary
Agreements. This Agreement and the Ancillary Agreements, when executed and
delivered by the Investor, will constitute valid and legally binding obligations
of the Investor, enforceable in accordance with their respective terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors' rights
generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and
-12-
(iii) to the extent the indemnification provisions contained in the Investors'
Rights Agreement may be limited by applicable laws and principles of public
policy.
4.2 Purchase Entirely for Own Account. This Agreement is made
with the Investor in reliance upon the Investor's representation to the Company,
which by the Investor's execution of this Agreement the Investor hereby
confirms, that the Shares and the Common Stock issuable upon conversion thereof
will be acquired for investment for the Investor's own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof,
and that the Investor has no present intention of selling, granting any
participation in, or otherwise distributing the same. By executing this
Agreement, the Investor further represents that the Investor does not have any
contract, undertaking, agreement or arrangement with any person to sell,
transfer or grant participations to the person or to any third person with
respect to any of the Shares and the Common Stock issuable upon conversion
thereof.
4.3 Reliance upon Investor's Representations. The Investor
understands that the Shares are not, and any Common Stock acquired on conversion
thereof at the time of issuance may not be, registered under the Securities Act
on the ground that the sale provided for in this Agreement and the issuance of
the Shares hereunder is exempt from registration under the Securities Act
pursuant to Section 4(2) thereof, and that the Company's reliance on such
exemption is predicated on the Investor's representations set forth herein.
4.4 Disclosure of Information. The Investor believes it has
received all the information the Investor considers necessary or appropriate for
deciding whether to purchase the Shares. The Investor has had an opportunity to
ask questions and receive answers from the Company regarding the terms and
conditions of the offering of the Shares and the Company's business, properties,
prospects and financial condition and to obtain additional information (to the
extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify the accuracy of any
information furnished to the Investor or to which the Investor had access. The
foregoing, however, does not limit or modify the representations and warranties
of the Company in Section 2 of this Agreement or the right of the Investor to
rely thereon.
4.5 Investment Experience; Economic Risk. The Investor
understands that the Company has a limited financial and operating history and
that an investment in the Company involves substantial risks. The Investor is
experienced in evaluating and investing in private placement transactions of
securities of companies in a similar stage of development to that of the Company
and acknowledges that the Investor is able to fend for himself, herself or
itself. The Investor has such knowledge and experience in financial and business
matters that the Investor is capable of evaluating the merits and risks of the
investment in the Shares. The Investor can bear the economic risk of the
Investor's investment and is able, without impairing the Investor's financial
condition, to hold the Shares and the Common Stock issuable upon conversion
thereof for an indefinite period of time and to suffer a complete loss of the
Investor's investment.
4.6 Accredited Investor Status. The Investor is an Accredited
Investor, as such term is defined in Regulation D promulgated under the
Securities Act.
-13-
4.7 Residency. The state of the Investor's principal place of
business is Texas.
4.8 Restricted Securities. The Investor understands that the
Shares and the Common Stock issuable upon conversion thereof are characterized
as "restricted securities" under the federal securities laws inasmuch as they
are being acquired from the Company in a transaction not involving a public
offering and that under such federal securities laws and applicable regulations
such Shares and the Common Stock issuable upon conversion thereof may be resold
without registration under the Securities Act only in certain limited
circumstances. In this connection, the Investor represents that it is aware of
the provisions of Rule 144 promulgated under the Securities Act which permit
limited resale of shares purchased in a private placement subject to the
satisfaction of certain conditions, including, among other things, the existence
of a public market for the shares, the availability of certain current public
information about the Company, the resale occurring not less than one year after
a party has purchased and paid for the security to be sold, the sale being
effected through a "broker's transaction" or in transactions directly with a
"market maker" and the number of shares being sold during any three-month period
not exceeding specified limitations.
4.9 Brokers or Finders. The Company has not, and will not,
incur, directly or indirectly, as a result of any action taken by the Investor,
any liability for brokerage or finders' fees or agents' commissions or any
similar charges in connection with this Agreement.
4.10 Further Limitations on Disposition. Without in any way
limiting the representations set forth above, the Investor further agrees not to
make any disposition of all or any portion of the Shares and the Common Stock
issuable upon conversion thereof unless and until (X) there is then in effect a
registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration
statement or (Y) the Investor shall have notified the Company of the proposed
disposition and shall have furnished the Company with a detailed statement of
the circumstances surrounding the proposed disposition, and if reasonably
requested by the Company, the Investor shall have furnished the Company with an
opinion of counsel, reasonably satisfactory to the Company, that such
disposition will be exempt from registration under the Securities Act.
Notwithstanding the foregoing, no such registration statement or opinion of
counsel shall be necessary for a transfer by the Investor to any person that
directly, or indirectly through one or more intermediaries, controls or is
controlled by, or is under common control with, the Investor; provided, however,
that, in such case, the transferee agrees in writing to be subject to the terms
of this Agreement to the same extent as if it were the original Investor
hereunder.
4.11 Legends. The Investor understands and agrees that the
certificates evidencing the Shares and any Common Stock issuable upon conversion
thereof shall bear the following legend (in addition to any legend required by
the Ancillary Agreements or under applicable state securities laws):
"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED,
-14-
PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH
ACT AND/OR APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE
CORPORATION HAS RECEIVED AN OPINION OF COUNSEL OR OTHER
EVIDENCE, REASONABLY SATISFACTORY TO THE CORPORATION AND ITS
COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED."
5. Conditions to Closing of the Investor.
5.1 Conditions Applicable to All Closings. The obligations of
the Investor under Section 1.2 of this Agreement upon the date of any Closing
are subject to the fulfillment on or before the applicable Closing of each of
the following conditions:
(a) Representations and Warranties Correct. The
representations and warranties of the Company contained in Section 2, as
modified or qualified by the Company in an updated Schedule of Exceptions, which
updated Schedule of Exceptions shall be delivered at least two (2) business days
prior to the date of the applicable Closing, shall be true and correct in all
material respects on and as of the applicable Closing with the same effect as
though such representations and warranties had been made on and as of the date
of the Closing. The representations and warranties of the Company contained in
the Collaboration and License Agreement, as modified or qualified by the terms
of that agreement, shall be true and correct in all material respects on and as
of the applicable Closing with the same effect as though such representations
and warranties had been made on and as of the date of the Closing.
(b) Covenants. All covenants, agreements and
conditions contained in this Agreement to be performed by the Company on or
prior to the applicable Closing shall have been performed or complied with in
all material respects.
(c) Compliance Certificate. The Company's President
or Chief Executive Officer shall deliver to the Investor at the applicable
Closing a certificate certifying that the conditions specified in Sections
5.1(a), (b) and (f) and, if applicable, Section 5.4(b), 5.5(b) or 5.6(b), have
been fulfilled.
(d) Qualifications. The Company shall have obtained
all necessary Blue Sky law permits and qualifications, or have the availability
of exemptions therefrom, required by any state for the offer and sale of the
Shares and the Common Stock issuable upon conversion thereof.
(e) Proceedings and Documents. All corporate and
other proceedings in connection with the transactions contemplated at the
Closing and all documents incident thereto shall be reasonably satisfactory in
form and substance to the Investor's special counsel, which shall have received
all such counterpart original and certified or other copies of such documents as
it may reasonably request.
-15-
(f) Material Adverse Change. Since the date of the
immediately preceding Closing (or since the date of this Agreement, in the case
of the Closing of the Initial Investment), there shall not have occurred any
event, change or effect that is materially adverse to the condition (financial
or otherwise), properties, assets or operations of the Company, taken as a
whole.
5.2 Conditions Applicable to the Closing of the Initial
Investment. The obligations of the Investor under Section 1.2(a) of this
Agreement are subject to the fulfillment on or before the date of the Closing of
the Initial Investment of each of the following conditions (in addition to those
set forth in Section 5.1):
(a) Secretary's Certificate. The Company shall have
delivered to the Investor a certificate of the Company executed by the Company's
Secretary, dated as of the Closing, certifying to the truth and correctness of
the Restated Certificate, the Bylaws and the board and stockholder resolutions
adopted in connection with the transactions contemplated by this Agreement.
(b) Restated Certificate. The Restated Certificate
shall have been filed with and certified by the
Delaware Secretary of State.
(c) Investors' Rights Agreement. The Company shall
have executed and delivered the Investors' Rights Agreement.
(d) Co-Sale Agreement. The Company and the Executives
(as defined in the Co-Sale Agreement) shall have executed and delivered the
Co-Sale Agreement.
(e) Opinion of Company Counsel. The Investor shall
have received from ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, the Company's corporate counsel, an
opinion, dated the date of the Closing of the Initial Investment, in the form
attached to this Agreement as Exhibit F.
(f) Collaboration and License Agreement. The Company
and the Investor shall have entered into a Collaboration and License Agreement
(the "Collaboration and License Agreement") satisfactory in form and substance
to the Investor (as determined in the Investor's sole discretion), and the
Investor shall have received all such counterpart original and certified or
other copies of such Collaboration and License Agreement, and any related
documents, as it may reasonably request.
(g) Agreement with [*] University. The Company
shall have entered into an agreement with [*] University satisfactory in
form and substance to the Investor.
(h) Agreement with [*] University. The Company
shall have entered into a license agreement with [*] University
satisfactory in form and substance to the Investor.
(i) The Company shall have entered into a Repurchase
Option Agreement, in the form attached to this Agreement as Exhibit G, with [*].
----------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-16-
5.3 Conditions Applicable to the Closing of each Quarterly
Investment. The obligations of the Investor under Section 1.2(b) of this
Agreement are subject to the fulfillment on or before the date of the Closing of
the applicable Quarterly Investment of each of the following conditions (in
addition to those set forth in Section 5.1):
(a) Collaboration and License Agreement. The
Collaboration and License Agreement shall be in full force and effect as of the
date of the applicable Closing, and the Investor shall not have received notice
of termination of the Collaboration and License Agreement on or prior to the
date of the applicable Closing.
(b) Research Program. The Research Program (as
defined in the Collaboration and License Agreement) shall not have been
terminated by either party as of the date of the applicable Closing, and the
Investor shall not have received notice of termination of the Research Program
on or prior to the date of the applicable Closing.
(c) Agreement with [*] University. The agreement with
[*] University described in Section 5.2(h) shall be in full force and effect as
of the date of the applicable Closing, and the Company shall not have received
or given notice of termination of that agreement on or prior to the date of the
applicable Closing.
(d) Agreement with [*] University. The license
agreement with [*] University described in Section 5.2(i) shall be in full force
and effect as of the date of the applicable Closing, and the Company shall not
have received or given notice of termination of that agreement on or prior to
the date of the applicable Closing..
5.4 Conditions Applicable to the Closing of the First
Milestone Investment. The obligations of the Investor under Section 1.2(c) of
this Agreement are subject to the fulfillment on or before the date of the
Closing of the First Milestone Investment of the following conditions (in
addition to those set forth in Sections 5.1 and 5.3):
(a) The final study report upon first completion of a
Phase I clinical study of the first Licensed Product by the Company shall have
been completed.
(b) In the event that the Company is receiving
Investor Common Stock at such Closing pursuant to Section 1.1(c), the
representations and warranties of the Company contained in Section 3 shall be
true and correct on and as of the Closing of the First Milestone Investment with
the same effect as though such representations and warranties had been made on
and as of the date of such Closing.
5.5 Conditions Applicable to the Closing of each Second
Milestone Investment. The obligations of the Investor under Section 1.2(d) of
this Agreement are subject to the fulfillment on or before the date of the
Closing of each Second Milestone Investment of the following conditions (in
addition to those set forth in Sections 5.1 and 5.3):
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-17-
(a) The final study report upon first completion of a
Phase II clinical study of the first Licensed Product of one of the first three
Distinct [*] Vectors by the Company shall have been completed.
(b) In the event that the Company is receiving
Investor Common Stock at such Closing pursuant to Section 1.1(c), the
representations and warranties of the Company contained in Section 3 shall be
true and correct on and as of the Closing of the applicable Second Milestone
Investment with the same effect as though such representations and warranties
had been made on and as of the date of such Closing.
5.6 Conditions Applicable to the Closing of each Third
Milestone Investment. The obligations of the Investor under Section 1.2(e) of
this Agreement are subject to the fulfillment on or before the date of the
Closing of each Third Milestone Investment of the following conditions (in
addition to those set forth in Sections 5.1 and 5.3):
(a) The final study report upon first completion of a
Phase III clinical study of the first Licensed Product of one of the first three
Distinct [*] Vectors by the Company shall have been completed.
(b) In the event that the Company is receiving
Investor Common Stock at such Closing pursuant to Section 1.1(c), the
representations and warranties of the Company contained in Section 3 shall be
true and correct on and as of the Closing of the applicable Third Milestone
Investment with the same effect as though such representations and warranties
had been made on and as of the date of such Closing.
6. Conditions to Closing of Company.
6.1 Conditions Applicable to All Closings. The obligations of
the Company to the Investor under this Agreement upon the date of any Closing
are subject to the fulfillment on or before the applicable Closing of each of
the following conditions by the Investor:
(a) Representations. The representations and
warranties of the Investor contained in Section 4 shall be true on and as of the
Closing with the same effect as though such representations and warranties had
been made on and as of the date of the Closing.
(b) Blue Sky. The Company shall have obtained all
necessary Blue Sky law permits and qualifications, or have the availability of
exemptions therefrom, required by any state for the offer and sale of the Shares
and the Common Stock issuable upon conversion thereof.
6.2 Conditions Applicable to the Closing of the Initial
Investment. The obligations of the Company under Section 1.2(a) of this
Agreement are subject to the fulfillment on or before the date of the Closing of
the Initial Investment of each of the following conditions (in addition to those
set forth in Section 6.1):
(a) Restated Certificate. The Restated Certificate
shall have been filed with and certified by the
Delaware Secretary of State.
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-18-
(b) Investors' Rights Agreement. The Investor shall
have executed and delivered the Investors' Rights Agreement.
(c) Co-Sale Agreement. The Investor shall have
executed and delivered the Co-Sale Agreement.
7. Investor's Purchase Right.
7.1 Purchase Option. The Company and the Stockholders hereby
agree that the Investor shall have the right (the "Option") to acquire all of
the issued and outstanding securities of the Company not then held by the
Investor, including all outstanding options (whether vested or unvested),
warrants and other securities convertible into or exchangeable or exercisable
for Company capital stock (collectively, the "Non-Investor Shares") at any time
on or prior to the fifth anniversary of the Effective Date (the "Purchase
Period"), on the following terms:
(a) Purchase. Upon the [*] by the Investor, the price
per share paid by the Investor for each Non-Investor Share (assuming the
exercise, exchange or conversion of all securities exercisable or exchangeable
for or convertible into Company capital stock) shall be [*] (as defined below);
provided, however, if the aggregate consideration paid by the Investor for [*]
(as defined below), the applicable Per Share Purchase Price shall be [*];
provided, further, however, that in the event that after the Effective Date the
Company grants options pursuant to the Stock Plan to purchase its Common Stock
to its employees or consultants who were not employees or consultants of the
Company as of the Effective Date, the Maximum Purchase Price shall be [*] (as
defined below).
(b) Certain Definitions. For the purposes of this
Section 7, the "Per Share Purchase Price," "Maximum Purchase Price" and "Maximum
Option Purchase Price" shall be determined based on the date that the Investor
is deemed to deliver notice of the exercise of the Option to the Company, as set
forth in the following table:
DATE NOTICE OF EXERCISE IS
DEEMED DELIVERED PER SHARE PURCHASE PRICE MAXIMUM PURCHASE PRICE MAXIMUM OPTION PURCHASE PRICE
-------------------------- ------------------------ ---------------------- -----------------------------
[*] [*] [*] [*]
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-19-
DATE NOTICE OF EXERCISE IS
DEEMED DELIVERED PER SHARE PURCHASE PRICE MAXIMUM PURCHASE PRICE MAXIMUM OPTION PURCHASE PRICE
-------------------------- ------------------------ ---------------------- -----------------------------
[*] [*] [*] [*]
(c) [*] Upon IPO.
(i) In the event that the Company
contemplates an initial public offering of its securities (the "IPO"), the
Company shall provide notice (the "IPO Notice") to the Investor of such IPO at
least [*] days prior to the date of filing (the "IPO Filing Date") of the
Company's registration statement for the IPO with the Securities and Exchange
Commission.
(ii) If the IPO Notice is timely given by
the Company and [*] (as set forth in the IPO Notice), then [*] provided,
however, that in the event that after giving the IPO Notice the Company [*] as
otherwise set forth in this Section 7.
(iii) Other than as set forth in Section
7.1(c)(ii), [*] to the Company.
7.2 Acquisition Agreement. Upon the exercise of the Option by
the Investor, the Company and the Investor shall in good faith [*].
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
-20-
7.3 Assignment of Option. The Investor may assign the Option
to any person by providing notice of such assignment to the Company. Such
assignment by the Investor shall not require the consent of the Company or the
Stockholders. For the purposes of this Section 7, the term "Investor" shall
include any assignee of the Option.
7.4 Further Agreements. If the Option is exercised by the
Investor, each of the parties to this Agreement agrees to use its best efforts
to take, or cause to be taken, all actions and to do or cause to be done all
things necessary, proper or advisable under applicable laws and regulations to
consummate and make effective the transactions contemplated by the Option,
including, but not limited to, obtaining any necessary stockholder, governmental
or third party approvals. Except as required by the federal securities laws,
statues, rules or regulations, no party to this Agreement shall publicly
disclose the existence of the Option without the written consent of the
nondisclosing party. The Company covenants and agrees, while the Option is in
effect, not to sell, lease, license or otherwise transfer any of the Company's
assets or any interest in the Company's assets to any third party (including,
without limitation, any parent, subsidiary or affiliate of the Company), or take
any other action the effect of which would be to reduce the value of the Company
or the Option, except in the ordinary course of business and consistent with
past practice or with the prior written consent of the Investor.
7.5 Stockholder Execution of this Agreement. The Company
agrees to use its best efforts to cause all current and future holders of
capital stock of the Company, including all outstanding options (whether vested
or unvested), warrants and other securities convertible into or exchangeable or
exercisable for Company capital stock, to execute and become a party to this
Agreement. Upon the execution of this Agreement by any such person, such person
shall become a party to this Agreement as a "Stockholder" and shall be listed on
Schedule A hereto.
8. Miscellaneous.
8.1 Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL
RESPECTS BY THE INTERNAL LAWS OF THE STATE OF
DELAWARE AS APPLIED TO AGREEMENTS
ENTERED INTO AMONG
DELAWARE RESIDENTS TO BE PERFORMED ENTIRELY WITHIN
DELAWARE,
WITHOUT REGARD TO CONFLICT OF LAWS RULES.
8.2 Survival of Warranties. The representations, warranties
and covenants of the Company and the Investor contained herein or made pursuant
to this Agreement shall survive for two years from the date of the applicable
Closing.
8.3 Successors and Assigns. Except as otherwise provided
herein, the provisions of this Agreement shall inure to the benefit of, and be
binding upon, the respective successors, assigns, heirs, executors and
administrators of the parties to this Agreement. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties
to this Agreement or their respective successors and assigns any rights,
remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.
-21-
8.4 Entire Agreement. This Agreement, including the exhibits
attached to this Agreement, and the other documents delivered pursuant to this
Agreement constitute the full and entire understanding and agreement among the
parties with regard to the subject matter hereof and thereof, and no party shall
be liable or bound to any other party in any manner by any warranties,
representations or covenants except as specifically set forth herein or therein.
8.5 Amendment. Except as expressly provided herein, neither
this Agreement nor any term of this Agreement may be amended, waived, discharged
or terminated other than by a written instrument signed by the party against
whom enforcement of any such amendment, waiver, discharge or termination is
sought.
8.6 Notices. All notices and other communications required or
permitted under this Agreement shall be in writing and shall be delivered
personally by hand or by courier, mailed by United States first-class mail,
postage prepaid, sent by facsimile or sent by electronic mail directed (a) if to
the Investor, at the Investor's address, facsimile number or electronic mail
address set forth on the Investor's signature page to this Agreement, or at such
other address, facsimile number or electronic mail address as the Investor may
designate by ten (10) days' advance written notice to the Company, (b) if to the
Company, to its address or facsimile number set forth on its signature page to
this Agreement and directed to the attention of the President, or at such other
address or facsimile number as the Company may designate by ten (10) days'
advance written notice to the Investor and (c) if to a Stockholder, at such
Stockholder's address, facsimile number or electronic mail address set forth in
the Company's records (which information the Company shall promptly provide to
the Investor upon request). All such notices and other communications shall be
deemed given upon personal delivery, on the date of mailing, upon confirmation
of facsimile transfer or when directed to the appropriate electronic mail
address.
8.7 Delays or Omissions. Except as expressly provided herein,
no delay or omission to exercise any right, power or remedy accruing to the
Investor, upon any breach or default of the Company under this Agreement, shall
impair any such right, power or remedy of the Investor nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of
any similar breach or default thereafter occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of
any kind or character on the part of the Investor of any breach or default under
this Agreement, or any waiver on the part of the Investor of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under
this Agreement or by law or otherwise afforded to the Investor, shall be
cumulative and not alternative.
8.8 Finder's Fees. With respect to any finder's fees arising
out of the purchase of the Shares pursuant to this Agreement:
(a) The Company hereby agrees to indemnify and to
hold the Investor harmless of and from any liability for any commission or
compensation in the nature of a finder's fee to any broker or other person or
firm (and the costs and expenses of defending against such
-22-
liability or asserted liability) for which the Company or any of its employees
or representatives are responsible.
(b) The Investor hereby agrees to indemnify and to
hold the Company harmless of and from any liability for any commission or
compensation in the nature of a finder's fee to any broker or other person or
firm (and the costs and expenses of defending against such liability or asserted
liability) for which the Investor or any of its employees or representatives,
are responsible.
8.9 Expenses. Each party shall pay all costs and expenses that
such party incurs with respect to the negotiation, execution, delivery and
performance of this Agreement.
8.10 Attorney's Fees. If any action at law or in equity is
necessary to enforce or interpret the terms of this Agreement, the Ancillary
Agreements or the Restated Certificate, the prevailing party shall be entitled
to reasonable attorney's fees, costs and necessary disbursements in addition to
any other relief to which such party may be entitled.
8.11 Severability. In the event that any provision of this
Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable or void, this Agreement shall continue in full force and
effect without said provision; provided that no such severability shall be
effective if it materially changes the economic benefit of this Agreement to any
party.
8.12 Interpretation. The words "include," "includes" and
"including" when used herein shall be deemed in each case to be followed by the
words "without limitation." The titles and subtitles used in this Agreement are
used for convenience only and are not considered in construing or interpreting
this Agreement.
8.13 Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be enforceable, and all of which
together shall constitute one instrument.
8.14 Telecopy Execution and Delivery. A facsimile, telecopy or
other reproduction of this Agreement may be executed by one or more parties to
this Agreement, and an executed copy of this Agreement may be delivered by one
or more parties to this Agreement by facsimile or similar electronic
transmission device pursuant to which the signature of or on behalf of such
party can be seen, and such execution and delivery shall be considered valid,
binding and effective for all purposes. At the request of any party to this
Agreement, all parties to this Agreement agree to execute an original of this
Agreement as well as any facsimile, telecopy or other reproduction of this
Agreement.
8.15 Adjustments. In the event that after the Effective Date
the Company shall effect a stock dividend, stock split, combination,
reorganization, recapitalization, reclassification or other similar event with
respect to its any class or series of its capital stock, then the "Per Share
Purchase Price" and any share or option numbers referenced in Section 7 hereof
shall be adjusted as appropriate to effect the intent of the parties hereto;
provided, however, that the "Maximum Purchase
-23-
Price" and "Maximum Option Purchase Price" shall not be subject to any such
adjustment. In the event that after the Effective Date the Company shall effect
a stock dividend, stock split, combination, reorganization, recapitalization,
reclassification or other similar event with respect to the Series A Preferred
Stock, then the number of Shares purchased by the Investor at each Closing
thereafter and the price per Share paid by the Investor at each Closing
thereafter shall be adjusted as appropriate to effect the intent of the parties
hereto.
-24-
IN WITNESS WHEREOF, the parties have executed this Agreement on the
day, month and year first set forth above.
"COMPANY"
VirRx, Inc.
By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇
----------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇, President
Address:
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇
▇▇. ▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Facsimile #: ▇▇▇-▇▇▇-▇▇▇▇
[*]
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
"INVESTOR"
Introgen Therapeutics, Inc.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇
----------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇
--------------------------------------
Title: President and CEO
-------------------------------------
Address:
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
[*]
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
"STOCKHOLDER"+
[*]
-------------------------------------------
(Signature)
[*]
-------------------------------------------
(Print Name of Stockholder)
-------------------------------------------
(Title, if signing on behalf of an entity)
+Executes this Agreement solely for the
purposes of Section 7 hereof.
VIRRX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
SIGNATURE PAGE
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
SCHEDULE A
Schedule of Stockholders
[*]
----------
* Certain information on this page has been omitted and filed separately
with the Commission. Confidential treatment has been requested with
respect to the omitted portions.
S-1
EXHIBIT A
Form of Amended and Restated Certificate of Incorporation
[omitted]
E-1
EXHIBIT B
Schedule of Exceptions
[omitted]
E-2
EXHIBIT C
Form of Investors' Rights Agreement
[omitted]
E-3
EXHIBIT D
Form of Right of First Refusal and Co-Sale Agreement
[omitted]
E-4
EXHIBIT E
Form of Proprietary Information and Inventions Assignment Agreement
[omitted]
E-5
EXHIBIT F
Form of Opinion of Company Counsel
[omitted]
E-6
EXHIBIT G
Form of Repurchase Option Agreement
[omitted]
E-7